Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 21, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - September 21, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/14/17 - "Crystalline Form of Afatinib Dimaleate" in Patent Application Approval Process (USPTO 20170240533)
By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventors SINGH, Shravan Kumar; VERMA, Shyam Sunder; SINGH, Kaptan; PRASAD, Mohan, filed on October 1, 2015, was made available online on August 31, 2017, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This
9/14/17 - "Methods and Compositions for Treating a Subject with a Smad7 Antisense Oligonucleotide" in Patent Application Approval Process (USPTO 20170240893)
By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventor Monteleone, Giovanni, filed on October 16, 2015, was made available online on August 31, 2017, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent application is assigned to Nogra Pharma Lim
9/14/17 - Alexion closing RI manufacturing facility
SMITHFIELD One year after breaking ground at the site of what was supposed to be an expanded facility, global pharmaceutical company Alexion announced Tuesday morning that it would be closing its Rhode Island manufacturing facility in Smithfield. The Smithfield site, which employs approximately 250 people, will be closed in a phased manner
9/14/17 - Alliance Pharma sales rise as key products inject healthy growth
SPECIALTY drugmaker Alliance Pharma's sales jumped in the first half of the year as its two key drugs boosted revenues. Alliance bought rival Sinclair Pharma's healthcare assets for 128 m in December 2015, and the firm has now completed the integration of the 27 products it acquired, which effectively doubled the size of the group. Chairman Andre
9/14/17 - Ascelia Pharma strengthens its oncology product portfolio
CMC Contrast AB acquires Oncoral Pharma Aps to further strengthen its product portfolio within oncology. In connection with the acquisition, the company is re-named to Ascelia Pharma AB. MangoralTM has been granted US Orphan Drug Designation by FDA for use in this indication.
9/14/17 - ASIT biotech Announces the Publication of its 2017 Half-Year Financial Report
ASIT biotech, a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces the publication of its 2017 half-year financial report. The document can be downloaded on the website of the Company under the...
9/14/17 - Astrazeneca, Aspen Enter Deal For Remaining Rights To Anaesthetic Medicines
LONDON- Drug maker AstraZeneca plc. said that it has entered into an agreement with Aspen Global Incorporated or AGI, part of the Aspen Group, under which AGI will now acquire the residual rights to the established anaesthetic medicines comprising of Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.
9/14/17 - AURIGENE, CURIS TIE UP FOR CANCER DRUG TRIAL IN INDIA
Aurigene Discovery Technologies Limited, a 100 percent subsidiary of Dr Reddy's Laboratories will conduct phase-II trial of CA-170, a potential drug to treat some cancers with Curis Inc at select sites in India. The Phase-I trial was conducted in the US, South Korea and Spain. ADTL will enjoy commercial rights to the programme in India and Russia a
9/14/17 - BiondVax Announces Pricing of Public Offering of American Depositary Shares
NESS ZIONA, Israel, Sept. 13, 2017/ PRNewswire/ BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, announced today that it has priced an underwritten public offering of 1,500,000 American Depositary Shares, each ADS representing forty of its
9/14/17 - Biosimilar User Fee Rates for Fiscal Year 2018
The Federal Food, Drug, and Cosmetic Act, as amended by the Biosimilar User Fee Amendments of 2017, authorizes FDA to assess and collect user fees for certain activities in connection with biosimilar biological product development; review of certain applications for approval of biosimilar biological products; and each biosimilar biological product.
9/14/17 - Cherry Hill mom: Daughter's opioid death was caused by 'corporate greed' [Philly.com]
Claire McCaskill took aim during a hearing Tuesday at marketing practices by the pharmaceutical industry generally and the behavior of one company in particular: Insys Therapeutics Inc., which made the powerful opioid believed to have played a role in the death of 32- year-old Sarah Fuller in Camden County last year. Also testifying at the hearing
9/14/17 - CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
By a News Reporter-Staff News Editor at Gene Therapy Weekly Global biotherapeutics leader CSL Behring announced that it has agreed to acquire Calimmune, Inc., a biotechnology company focused on the development of ex vivo hematopoietic stem cell gene therapy with R&D facilities in Pasadena, California and Sydney, Australia for an upfront payment o
9/14/17 - Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast Cancer
By a News Reporter-Staff News Editor at Women's Health Weekly Daiichi Sankyo Company, Limited announced the initiation of DESTINY-Breast01, a pivotal phase 2 study evaluating the safety and efficacy of investigational HER2-targeting antibody drug conjugate DS-8201 in patients with HER2-positive unresectable and/or metastatic breast cancer...
9/14/17 - Drug Companies Fear Release of the New AloeCure
Big Pharma stands to lose billions as doctors' recommend drug-free "health cocktail" that adjusts and corrects your body's health conditions. Drug company execs are nervous. That's because the greatest health advance in decades has hit the streets.
9/14/17 - Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Files An 8-K Regulation FD Disclosure
Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure. Eagle Pharmaceuticals,Inc., or the Company, will present the attached presentation of the Company's business model, products and product candidates at the Morgan Stanley 15thAnnual Global Healthcare Conference in New York, New York on
9/14/17 - Experts release US policy roadmap to reduce antibiotics used in food animals
Yet, according to a new report released, the U.S. policy response fails to adequately address this major challenge. The commission report was authored by 12 antibiotic resistance experts from the fields of infectious disease medicine, veterinary medicine, microbiology, epidemiology and public health, including Co-Chair Lance Price, PhD, Director of
9/14/17 - FASLODEX fulvestrant Receives US FDA Approval as Monotherapy for Expanded Use in HR+, HER2- Advanced Breast Cancer
By a News Reporter-Staff News Editor at Politics& Government Week AstraZeneca announced that the US Food and Drug Administration has approved FASLODEX 500 mg as monotherapy for expanded use in women with hormone-receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer, who have gone through menopause and have
9/14/17 - FDA approves first biosimilar for the treatment of cancer
The U.S. Food and Drug Administration today approved Mvasi as a biosimilar to Avastin for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer. "We'll continue to work hard to ensure that biosimilar medications are brought to the market quickly, through a process that makes certa
9/14/17 - FDA approves new treatment for adults with relapsed follicular lymphoma
"For patients with relapsed follicular lymphoma, the cancer often comes back even after multiple treatments," said Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. The National Cancer Institute at the
9/14/17 - FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF) Files An 8-K Financial Statements and Exhibits
FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF) Files An 8-K Financial Statements and ExhibitsItem 9.01 Financial Statements and Exhibits. FENNEC PHARMACEUTICALS INC. ExhibitEX-99.1 2 v475143-ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES LISTING ON THE NASDAQ CAPITAL MARKET Trading on Nasdaq under t
9/14/17 - Findings on Poultry Farming Reported by Investigators at Bahauddin Zakariya University (A review of beta-glucans as a growth promoter and antibiotic...
Findings on Poultry Farming Reported by Investigators at Bahauddin Zakariya University. Our news editors obtained a quote from the research from Bahauddin Zakariya University, "As the occurrence of antibiotic resistance is a serious problem, there is increased pressure on producers to reduce antibiotic use in poultry production. For more informatio
9/14/17 - Global Quit Smoking Drug Market 2017 - Aradigm, Roche, BGP Group, Boots, Cochrane Collaboration
The study of Quit Smoking Drug industry is very important to enhance business productivity and for the study of market forecast.Pune, India 09/13/2017 The Quit Smoking Drug Market 2017 examines the performance of the Quit Smoking Drug market, enclosing an in-depth judgment of the Quit Smoking Drug market state and the competitive landscape gl
9/14/17 - GNW-News: Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study (english)
Novartis International AG/ Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study. matches reference medicine Humira* safety and efficacy profile* Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatment of several immunological...
9/14/17 - GSK Announces Unanimous FDA Approval For Shingrix In Over 50s
LONDON- GlaxoSmithKline Plc announced Thursday that the Vaccines and Related Biological Products Advisory Committee or VRBPAC of the US Food and Drug Administration voted unanimously that the data support the efficacy and safety of Shingrix for the prevention of herpes zoster or shingles in adults ages 50 and over. FDA Advisory Committees provide..
9/14/17 - Indian Firm Working to Cure Ailments via Generic Medicine
As the world grapples with becoming enlightened on the benefits of generic medicine to modern times, an Indian firm, Gallene Sciences based in Suramya Complex, Ahmedabad, has stated that it hopes to continue being a major global player in the field. In a statement by the firm s chief executive officer, Vivek Narendrakumar Mapara, the firm, which
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415